Application of immune cells containing a reporter system expressing cd54 and cloned novel cells
A technology of immune cells and reporting systems, applied in the application field of immune cells, can solve problems such as not appearing
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0046] Establishment of ITRI-54M cells
[0047] According to the manufacturer's operating instructions of the LVX-MetLuc (Clontech, PT4422-5) plasmid, the LVX-MetLuc plasmid was treated with BstB I and BamH I restriction enzymes, so that the CD54 promoter sequence (sequence identification number: 1) was transferred to LVX-MetLuc In the MetLuc plasmid, a CD54-promoter mLuc expression system (Fig. 1) is formed, wherein in this expression system, the sequence of the CD54 promoter-mLuc is the sequence of SEQ ID NO: 2. Then the formed CD54-promoter mLuc expression system was used Lenti-X TM Ready-To-Glow TM Secreted Luciferase Reporter System (Clontech, 631746) was transfected into 293FT cells to produce lentivirus (Lentivirus) with CD54-mLuc. THP-1 cells were then infected with this virus. The THP-1 cell line was cultured in THP-1 medium, and its composition was RPMI medium (GIBCO, 31800), containing 10% FBS (GIBCO, 10437), 4.5g / L glucose (Sigma, G7021), 10mM HEPES ( Sigma, H...
Embodiment 2
[0050] Determination of whether the substance to be tested is a skin sensitizer (or an immunomodulatory substance)
[0051] In this experiment, the process of judging whether the substance to be tested is a skin sensitizer is as follows: figure 2 shown. see figure 2 with detailed step-by-step instructions below.
[0052] 1. Toxicity test of the tested substance on ITRI-54M cells
[0053] ITRI-54M cells were cultured in THP-1 medium, which consisted of RPMI medium (GIBCO, 31800), containing 10% fetal bovine serum (GIBCO, 10437), 4.5g / L glucose (Sigma, G7021), 10mM HEPES (Sigma, H4034), 1x penicillin and streptomycin (Biowest, L0022), 1mM sodium pyruvate (sodiumpyruvate) (Biowest, L0642), 0.05mM 2-mercaptoethanol (GIBCO , 21985-023) and 0.5 μg / mL puromycin (puromycin).
[0054] The reference chemical samples listed in Table 1 with known allergenicity or the Chinese herbal extracts listed in Table 2 commonly used in cosmetics were mixed with an appropriate solvent (DMSO or...
Embodiment 3
[0086] Determination of whether the substance to be tested is an anti-inflammatory substance (or an immunomodulatory substance)
[0087] In this experiment, the process of judging whether the substance to be tested is a skin sensitizer is as follows: image 3 shown. see image 3 with detailed step-by-step instructions below.
[0088] 1. Toxicity test of the tested substance on ITRI-54M cells
[0089] ITRI-54M cells were cultured in THP-1 medium, which consisted of RPMI medium (GIBCO, 31800), containing 10% fetal bovine serum (GIBCO, 10437), 4.5g / L glucose (Sigma, G7021), 10mM HEPES (Sigma, H4034), 1x penicillin and streptomycin (Biowest, L0022), 1mM sodium pyruvate (sodiumpyruvate) (Biowest, L0642), 0.05mM 2-mercaptoethanol (GIBCO , 21985-023) and 0.5 μg / mL puromycin (puromycin).
[0090] The test substances listed in Table 6 known to have anti-inflammatory ability were dissolved in an appropriate solvent (DMSO or THP-1 culture solution without 2-ME) to form a stock solut...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


